2023 Hot Topic in Basic & Translational Science: Resistance to IO in NSCLC on November 10-12, 2023 in Brussels, Belgium

2023 Hot Topic in Basic & Translational Science: Resistance to IO in NSCLC on November 10-12, 2023 in Brussels, Belgium

MEETING OVERVIEW

The clinical application of the immune checkpoint inhibitors (ICIs) that target PD-1, PD-L1, and CTLA-4 have shown significant and durable survival increases for a subset of patients with advanced NSCLC. However, the challenge in the usage of ICIs in lung cancer remains in understanding the biology of resistance, including predictive biomarkers beyond PD-L1 expression and the factors controlling either de novo or acquired resistance. Join us to discuss and present new and emerging data on immunoresistance in NSCLC!

EXCEPTIONAL EDUCATION: Presentations will summarize information about ongoing clinical trials of the newest lung cancer therapies, including preclinical and early clinical data.

CONNECT & COLLABORATE: Build connections with colleagues from around the world including prominent researchers and physicians.

PRESENT & DISCUSS: Showcase your research and contribute to discussions that will shape the future of treatments in lung cancer and thoracic malignancies.

IMPORTANT DATES

Abstract Submission Opens June 7, 2023

Registration and Accommodation Booking Opens June 7, 2023

Abstract Submission Deadline August11, 2023

Notification of Abstract Acceptance/ Rejection September 4, 2023

Early Registration Deadline August 30, 2023

Regular Registration Deadline September 27, 2023

Meeting in Brussels, Belgium November 10 - 12, 2023


Sessions at a Glance:

  • Epigenetic & Genomic Mechanisms of Resistance
  • TME Contributors to Resistance
  • Host Factors Associated with Resistance
  • The Role of the Tumor Draining Lymphnode in Tumorigenesis & the Role of Tertiary Lymphoid Structure in Immune Resistance
  • Vaccination to (Re)activate the Immune System
  • Cell Therapy and T-Cell Engagers
  • Big Data Discovery of Novel Resistance Mechanisms
  • Resistance to Immune Checkpoint Blockade in the Clinic: Where Are We Now?
  • Poster Sessions
  • Faculty & Group Dinner(s)

Name: Intl. Assoc. for the Study of Lung Cancer (IASLC)
Website: http://iaslc.org
Address: 999 17th. Street, #200

The IASLC is a global multidisciplinary organization dedicated to the eradication of all forms of lung cancer. From the provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.
Related Events